This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Canasa/Salofalk rectal gel
Drug Names(s): Mesalamine
Description: The active ingredient is of this rectal gel is 5-ASA, a drug that acts to suppress inflammatory bowel disease. The mode of action of 5-ASA is still under investigation with several biochemical mechanisms being proposed. At present, the action of 5-ASA in treating inflammatory bowel disease appears to be associated with the metabolism of arachidonic acid. Studies suggest that interference of 5-ASA with either leukotriene or prostaglandin metabolism may play a major role in suppressing the inflammatory response mechanism.
Aptalis and Forest
In January 2014, Aptalis announced that it has signed a definitive agreement to be acquired by Forest Laboratories. Forest intends to acquire Aptalis from its shareholders for $2.9 billion in cash, pending required reviews by anti-trust authorities in the US and Canada. Forest expects to use a combination of cash on hand and debt to fund the transaction.
In February 2014, Forest Laboratories announced the completion of its acquisition of Aptalis, a privately held specialty pharmaceutical company focused on gastrointestinal disorders and cystic fibrosis. The companies will now begin combined operations, with Aptalis operating as a subsidiary of Forest Laboratories.
Forest and Actavis
In February 2014, Actavis and Forest announced that they have entered into a definitive agreement under which Actavis will acquire Forest for a combination of cash and equity valued at approximately $25 billion or $89.48 per Forest share ($26.04 in...See full deal structure in Biomedtracker
Canasa/Salofalk rectal gel News
Pink Sheet In Brief: Athena Neurosciences
Pink Sheet UpsherSmith
Additional information available to subscribers only: